Outcomes and Cosmesis With Whole Breast Irradiation and Boost

Description

This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.

Conditions

Early-stage Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.

Patient-Reported Outcomes and Cosmesis Following Five Fraction Whole Breast Irradiation With Simultaneous Integrated Boost

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

Condition
Early-stage Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Madison

UW Carbone Cancer Center, Madison, Wisconsin, United States, 53792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ability to understand and the willingness to sign a written informed consent document
  • * Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS
  • * Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx
  • * Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques
  • * Treatment plan includes breast tumor bed boost
  • * Willingness to comply with all study procedures and be available for the duration of the study
  • * Mastectomy of ipsilateral breast
  • * Lack of histologic diagnosis
  • * Histologic involvement of the axillary or regional nodes or metastatic disease
  • * Accelerated partial breast irradiation treatment plan
  • * Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin
  • * Previous history of chest radiation therapy
  • * Previous history of ipsilateral breast cancer
  • * Concurrent cytotoxic chemotherapy
  • * Active connective tissue disease including scleroderma
  • * Inability or unwillingness to return for required follow up visit

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Jessica Schuster, MD, PRINCIPAL_INVESTIGATOR, UW Carbone Cancer Center

Study Record Dates

2032-02